CN110215470A - A kind of preparation method of composition and drug and drug for treating diabetes - Google Patents
A kind of preparation method of composition and drug and drug for treating diabetes Download PDFInfo
- Publication number
- CN110215470A CN110215470A CN201910666939.4A CN201910666939A CN110215470A CN 110215470 A CN110215470 A CN 110215470A CN 201910666939 A CN201910666939 A CN 201910666939A CN 110215470 A CN110215470 A CN 110215470A
- Authority
- CN
- China
- Prior art keywords
- water
- drug
- balsam pear
- filtrate
- caulis sinomenii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 229940079593 drug Drugs 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 50
- 239000000706 filtrate Substances 0.000 claims abstract description 39
- 244000302512 Momordica charantia Species 0.000 claims abstract description 36
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 36
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims abstract description 35
- 235000018365 Momordica dioica Nutrition 0.000 claims abstract description 35
- 239000002775 capsule Substances 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 22
- 229920002472 Starch Polymers 0.000 claims abstract description 13
- 235000019698 starch Nutrition 0.000 claims abstract description 13
- 239000008107 starch Substances 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 11
- 230000008569 process Effects 0.000 claims abstract description 9
- 238000005469 granulation Methods 0.000 claims abstract description 8
- 230000003179 granulation Effects 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 238000000605 extraction Methods 0.000 claims abstract description 6
- 238000000643 oven drying Methods 0.000 claims abstract description 5
- 239000003596 drug target Substances 0.000 claims abstract description 3
- 238000001914 filtration Methods 0.000 claims description 30
- 239000002245 particle Substances 0.000 claims description 13
- 239000006071 cream Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 7
- 239000004744 fabric Substances 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims description 2
- 230000008719 thickening Effects 0.000 claims description 2
- 238000005453 pelletization Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 241001465754 Metazoa Species 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000001154 acute effect Effects 0.000 abstract description 2
- 239000000284 extract Substances 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 241000081623 Sabia parviflora Species 0.000 abstract 3
- 231100000403 acute toxicity Toxicity 0.000 abstract 1
- 231100001252 long-term toxicity Toxicity 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000002218 hypoglycaemic effect Effects 0.000 description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 9
- 239000008103 glucose Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 229940100389 Sulfonylurea Drugs 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000020925 non fasting Nutrition 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 2
- 244000241257 Cucumis melo Species 0.000 description 2
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010023129 Jaundice cholestatic Diseases 0.000 description 1
- 239000009022 Jinqi Substances 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 239000009220 Liuwei Dihuang Decoction Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 201000005267 Obstructive Jaundice Diseases 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 239000008882 Tang Maikang Substances 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 239000008661 Yangxinshi Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960001764 glibornuride Drugs 0.000 description 1
- RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960003468 gliquidone Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- -1 oral solution Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The preparation method of the composition and drug and drug that the invention discloses a kind of for treating diabetes, composition is using Sabia parviflora Wall.ex Roxb and balsam pear as main active, Sabia parviflora Wall.ex Roxb base of leaf mixes and adds water to cook extraction 3 times, amount of water is by subtracting, merge filtrate three times, Sabia parviflora Wall.ex Roxb extracting solution is made；Balsam pear shave, adds water to cook extraction 3 times, and each amount of water merges filtrate three times by subtracting, balsam pear extract is made；Merge the above two taste extracting solutions, is concentrated into thick paste；Soluble starch is added, fine powder is ground into after oven drying, wet process squeezes granulation, is packed into capsule or tabletting, obtains drug target.Drug of the present invention is confirmed through zoopery and clinical application, it is good to treat diabetes effect, each raw material proportioning plays synergistic function, and preparation process is simple, convenient for mechanization production, through animal is acute and long term toxicity test show it is without any side effects, it is highly-safe, provide the new selection of one kind for clinic.
Description
Technical field
The present invention relates to a kind of pharmaceutical compositions, and in particular to a kind of composition for treating diabetes and includes the group
Close the drug of object and the preparation method of the drug.
Background technique
Currently, the orally-taken blood sugar reducing Western medicine for the treatment of type-2 diabetes mellitus mainly has sulfonylureas and biguanides.Such as the newest second generation
Sulfonylureas drugs for diabetes have glibenclamide, Glipizide, gliclazide, Glibornuride, gliquidone etc..These drugs can really drop
Hypoglycemia has therapeutic effect to type-2 diabetes mellitus people, but side effect is very outstanding: (1) hypoglycemic reaction is serious, especially
It is to hepatic and kidney function obstacle and elderly patients, hypoglycemia still recurrent exerbation after drug withdrawal, very causes to cause central nervous system irreversible
Damage is lethal.(2) other side effects of have Nausea and vomiting, indigestion, cholestatic jaundice, hepatic disorder, white thin
Born of the same parents' reduction, agranulocytosis, alpastic anemia, hemolytic anemia, decrease of platelet, pruitus, fash and photosensitive skin
Rash etc..Common biguanides have metformin (metformin), phenethyldiguanide and buformin, such drug is to normal person
Hypoglycemic effect is had no, hypoglycemic effect can be enhanced by being used in combination with sulfonylureas.Major side effects are serious gastrointestinal reactions,
Show as dry hardship, metallic taste, anorexia, nausea,vomiting,diarrhea etc..
As described above, Western medicine hypoglycemic agent in addition to having blood sugar reducing function, still has apparent toxic side effect, and to glycerol three in blood
Rouge, cholesterol and low-density lipoprotein are it is not yet found that reduction acts on, that is to say, that they are generally existing to diabetes concurrent
Disease is without therapeutic effect outstanding.Therefore, find that less toxic side effect, hypoglycemic is curative for effect and has treatment again to complication from Chinese medicine
Effect, suitable for the drug of type 2 diabetes patient seem particularly necessary.
Have more than 30 related with treatment type-2 diabetes mellitus in existing domestic commercially available more than 5000 Chinese patent drug, they are: sweet dew
Wasting-thirst capsule, hypoglycemic first piece, anti-hydatic agent, Kelening capsule, Yangxinshi tablets, Yujinfang capsule, Yujinfang tablet, stilbene leech hypoglycemic
Capsule, Yuquan piece, good wine are quenched one's thirst particle, JINQI JIANGTANG PIAN, Shiwei Yuquan capsule, beneficial saliva oral liquid for decreasing blood sugar, three capsule for eliminating of Yu, sugar
Arteries and veins recovering particles, diabetes pill, Huazhuoqingshen Granules, promoting blood circulation source oral solution, vigor source slice, Jiangtang Shuxin capsule, Jiangtangwan pill, drop of quenching one's thirst
Sugar-tablet, Xiaokeping Tablets, hypoglycemic capsule, melbine of establishing the yang function, osmanthus attached glutinous rehmannia capsule, LIUWEIDIHUANG JIAONANG, three, which disappear, controls piece, ginseng-astragalus blood-sugar lowering
Piece joins quench one's thirst particle, Shiwei Yuquan capsule, Tangniaole capsule, capsule for lowering blood sugar and preventing thirst, diabetes pill, Liuwei Dihuang Wan, Maiwei-dihuang
Ball, TANGMAIKANG KELI.
Above-mentioned Chinese patent drug seems there is certain relaxation effect to certain symptoms of type-2 diabetes mellitus in clinical use, but whether
With therapeutic effect, it is difficult to make science judgment.Their major defect is:
1. above 30 several kinds are mostly that country in 1985 promulgates " provisions for new drugs approval " pervious old kind of tradition,
Drug effect and toxic side effect are difficult to affirm without scientific validation and evaluation；
2. the above kind is nearly all compound preparation, quality standard is mostly unable to control quality, each production batch product matter
Amount is difficult to unanimously, and contained active component or effective component is indefinite；
3. the above kind is mostly traditional backwardness dosage form, such as water pill, oral solution, mixture, the preparation of primary medicinal powder
Tablet, granule, capsule, there is no the Modern preparations made of single medicinal material active component；
4. the clinical orientation of most preparation is indefinite, some auxiliary therapeutic actions are only capable of, or make substantially without treatment
With, some drugs clinically only have seldom alleviation part symptom effect, also there is the preparation that Western medicine antidiabetic drug is added in Chinese medicine,
Hypoglycemic effect is affirmative, but it has been observed that toxic side effect is still inevitable.
Summary of the invention
For the above-mentioned prior art, the present invention provides a kind of composition for treating diabetes and comprising the composition
The preparation method of drug and the drug, to solve, existing Remedies for diabetes therapeutic effect is poor and side effect is big is asked
Topic.
In order to achieve the above object, the technical scheme adopted by the invention is that: provide a kind of for treating the group of diabetes
Close the preparation method of object, comprising the following steps:
S1: taking the little Hua caulis sinomenii of 5~22 mass parts, and base of leaf separated, and it is 0.5~1cm that leaf, which is then cut into width,
Strip, by stem be ground into diameter be 2~3mm particle, added water to cook after mixing extraction 3 times, merging filtrate obtains small cyanine wind
Rattan filtrate；
S2: the thin slice for taking the balsam pear of 5~33 mass parts, and being cut into a thickness of 0.2~0.5cm adds water to cook extraction 3 times,
Merging filtrate obtains balsam pear filtrate；
S3: merging little Hua caulis sinomenii filtrate and balsam pear filtrate, 60 mesh filter-cloth filterings, and centrifuge separation takes supernatant, and straight fire is dense
It is reduced to the clear cream that relative density is 1.10~1.20, it is 1.30~1.40 that relative density is concentrated into 60~70 DEG C of water-baths
Thick paste；
S4: gained thick paste in S3 is uniformly mixed with soluble starch by the mass ratio of 1:2~4, is sieved with 100 mesh sieve, wet process
Granulation is squeezed, the particle between 40~60 meshes, tabletting or loading capsule is collected, obtains drug target.
The preparation method of drug can do improvement further below in the present invention.
Further, little Hua caulis sinomenii decoction in S1 method particularly includes: 15~20 times of amounts are first added into cauline leaf mixture
Water decoct 0.5~1.5h, filtering, then into filter residue be added 10~15 times amount water decoct 0.5~1.5h, filtering, then to
The water that 10~15 times of amounts are added in filter residue decocts 0.5~1.5h, and filtering collects filtered filtrate three times, obtains little Hua caulis sinomenii
Filtrate.
Further, balsam pear decoction in S2 method particularly includes: the water that 10~15 times of amounts are first added into balsam pear thin slice decoct
1.5~3h, filtering, then into filter residue be added 8~12 times amount water decoct 1.5~3h, filtering, then into filter residue be added 6~
The water of 10 times of amounts decocts 0.5~1h, and filtering collects filtered filtrate three times, obtains balsam pear filtrate.
Further, the relative density of clear cream is 1.15 in S3, and the water-bath thickening temperature of clear cream is 65 DEG C, thick paste it is relatively close
Degree is 1.35.
Further, it pelletizes in S4 method particularly includes: first mix thick paste with the soluble starch for accounting for total amount 10% thoroughly, baking oven
Crushed after being dried adds remaining soluble starch at fine powder, and mixing is mixed, sieved with 100 mesh sieve, and wet process squeezes granulation.
The present invention is also claimed a kind of for treating the composition of diabetes, and the composition utilizes the original of following mass parts
It is prepared by material:
10~15 parts of little Hua caulis sinomenii,
10~15 parts of balsam pear；
Wherein, the water content of little Hua caulis sinomenii should control in the range of 8%~13%, and the water content of balsam pear should be controlled
System 40%~45%, balsam pear using dry or low temperature drying by the way of handled, so that melon body is obviously softened, drying temperature is not
Preferably more than 70 DEG C.
Based on the above technical solution, the present invention can also be improved as follows.
Further, composition is prepared using the raw material of following mass parts:
10 parts of little Hua caulis sinomenii,
15 parts of balsam pear.
The invention also discloses the drug comprising the composition for treating diabetes, the drug can for capsule,
Tablet, injection etc..
The beneficial effects of the present invention are: drug of the present invention is confirmed through zoopery and clinical application, diabetes effect is treated
Good, each raw material proportioning plays synergistic function, and preparation process is simple, is convenient for mechanization production, acute and long-term through animal
Toxicity test show it is without any side effects, it is highly-safe, provide a kind of new selection for clinic.
Detailed description of the invention
Fig. 1 is the preparation technology figure of drug of the present invention.
Specific embodiment
Below with reference to embodiment, specific embodiments of the present invention will be described in detail.
Embodiment one
It is a kind of for treating the composition of diabetes, the pharmaceutical composition using following mass parts raw material be made:
10 parts of little Hua caulis sinomenii,
15 parts of balsam pear.
Capsule is made in above-mentioned composition in the present embodiment, preparation process is as follows:
S1: taking 1kg water content is 10% or so little Hua caulis sinomenii, and base of leaf is separated, and leaf, which is then cut into width, is
Stem is ground into the particle that diameter is 2~3mm by the strip of 0.5~1cm；Then the water of 17 times of amounts is added into cauline leaf mixture
1h is decocted, filtering, then the water of 12 times of amounts of addition decocts 1h, filtering into filter residue, then 12 times of decoctings measured are added into filter residue
1h is boiled, is filtered, filtered filtrate three times is collected, obtains little Hua caulis sinomenii filtrate；
S2: taking 1.5kg water content is 40% or so balsam pear, and the thin slice being cut into a thickness of 0.2~0.5cm, first to hardship
The water decoction 2h of 12 times of amounts, filtering are added in melon thin slice, the water that 10 times of amounts are then added into filter residue decocts 2h, filters, then to
The water that 8 times of amounts are added in filter residue decocts 0.5h, and filtering collects filtered filtrate three times, obtains balsam pear filtrate；
S3: merging little Hua caulis sinomenii filtrate and balsam pear filtrate, 60 mesh filter-cloth filterings, and centrifuge separation takes supernatant, and straight fire is dense
It is reduced to the clear cream that relative density is 1.15 or so, the thick paste that relative density is 1.35 or so is concentrated into 65 DEG C of water-baths；
S4: weighing the soluble starch of 3 times of quality of thick paste obtained by S3, and first thick paste forms sediment with the soluble of total amount 10% is accounted for
Powder is mixed thoroughly, and the fine powder that partial size is 100 mesh or so is ground into after oven drying, adds remaining soluble starch, and mixing mixes,
It sieves with 100 mesh sieve, wet process squeezes granulation, collects the particle between 40~60 meshes, is packed into capsule, obtains target capsule.
Embodiment two
It is a kind of for treating the composition of diabetes, the pharmaceutical composition using following mass parts raw material be made:
20 parts of little Hua caulis sinomenii,
20 parts of balsam pear.
Tablet is made in above-mentioned composition in the present embodiment, preparation process is as follows:
S1: taking 2kg water content is 8% or so little Hua caulis sinomenii, and base of leaf is separated, and leaf, which is then cut into width, is
Stem is ground into the particle that diameter is 2~3mm by the strip of 0.5~1cm；Then the water of 20 times of amounts is added into cauline leaf mixture
1.5h is decocted, filtering, then the water of 15 times of amounts of addition decocts 1h, filtering into filter residue, then 10 times of water measured are added into filter residue
0.5h is decocted, filtering collects filtered filtrate three times, obtains little Hua caulis sinomenii filtrate；
S2: taking 2kg water content is 45% or so balsam pear, and the thin slice being cut into a thickness of 0.2~0.5cm, first to balsam pear
The water decoction 2h of 15 times of amounts, filtering are added in thin slice, the water that 12 times of amounts are then added into filter residue decocts 1.5h, filters, then to
The water that 6 times of amounts are added in filter residue decocts 1h, and filtering collects filtered filtrate three times, obtains balsam pear filtrate；
S3: merging little Hua caulis sinomenii filtrate and balsam pear filtrate, 60 mesh filter-cloth filterings, and centrifuge separation takes supernatant, and straight fire is dense
It is reduced to the clear cream that relative density is 1.20 or so, the thick paste that relative density is 1.40 or so is concentrated into 70 DEG C of water-baths；
S4: weighing the soluble starch of 4 times of quality of thick paste obtained by S3, and first thick paste forms sediment with the soluble of total amount 10% is accounted for
Powder is mixed thoroughly, and the fine powder that partial size is 100 mesh or so is ground into after oven drying, adds remaining soluble starch, and mixing mixes,
It sieving with 100 mesh sieve, wet process squeezes granulation, and the particle between 40~60 meshes is collected, the disk of diameter 0.5cm or so is pressed into,
Obtain target tablet.
Embodiment three
It is a kind of for treating the composition of diabetes, the pharmaceutical composition using following mass parts raw material be made:
20 parts of little Hua caulis sinomenii,
30 parts of balsam pear.
Capsule is made in above-mentioned composition in the present embodiment, preparation process is as follows:
S1: taking 2kg water content is 13% or so little Hua caulis sinomenii, and base of leaf is separated, and leaf, which is then cut into width, is
Stem is ground into the particle that diameter is 2~3mm by the strip of 0.5~1cm；Then the water of 15 times of amounts is added into cauline leaf mixture
0.5h is decocted, filtering, the water that 10 times of amounts are then added into filter residue decocts 1.5h, filtering, then 10 times of amounts are added into filter residue
Water decocts 1h, and filtering collects filtered filtrate three times, obtains little Hua caulis sinomenii filtrate；
S2: taking 3kg water content is 40% or so balsam pear, and the thin slice being cut into a thickness of 0.2~0.5cm, first to balsam pear
The water decoction 1.5h of 10 times of amounts, filtering are added in thin slice, the water that 8 times of amounts are then added into filter residue decocts 2.5h, filters, then to
The water that 6 times of amounts are added in filter residue decocts 0.5h, and filtering collects filtered filtrate three times, obtains balsam pear filtrate；
S3: merging little Hua caulis sinomenii filtrate and balsam pear filtrate, 60 mesh filter-cloth filterings, and centrifuge separation takes supernatant, and straight fire is dense
It is reduced to the clear cream that relative density is 1.10 or so, the thick paste that relative density is 1.30 or so is concentrated into 60 DEG C of water-baths；
S4: weighing the soluble starch of 2 times of quality of thick paste obtained by S3, and first thick paste forms sediment with the soluble of total amount 10% is accounted for
Powder is mixed thoroughly, and the fine powder that partial size is 100 mesh or so is ground into after oven drying, adds remaining soluble starch, and mixing mixes,
It sieves with 100 mesh sieve, wet process squeezes granulation, collects the particle between 40~60 meshes, is packed into capsule, obtains target capsule.
Interpretation of result
Curative effect is carried out to the drug comprising the composition for treating diabetes in the present invention by mouse experiment model
Detection.Experiment adds STZ that can induce C using high fat diet57BL/6J weanling mice generates type II diabetes, which is considered as
A kind of ideal animal model of diabetes mellitus type II.C57BL/6J mouse is that have abdominal obesity and type II diabetes gene tendency
Inbred mouse, have ob/ob genetic background, to fat induction blood glucose rise it is more sensitive, show as hyperglycemia and high pancreas islet
Element, giving high-sugar-fat-diet for a long time can induce type II diabetes model, which is closer to mankind's incidence.Experiment
Process is as follows:
1. experimental material
1.1. mouse
Cleaning grade C57BL/6J mouse (Shanghai Slac Experimental Animal Co., Ltd.), male, 45,3 week old, body
10~12g is weighed, quality certification number: SCXK (Shanghai) 2003-0003.
1.2. feed
High-sugar-fat-diet is prepared according to a conventional method.
1.3. drug and reagent
Drug prepared by embodiment one to three in the present invention；Isosorbide-5-Nitrae dithiothreitol dithio (DTT) (the raw work biology work in Shanghai
Cheng company, lot number: 020316)；Water saturation phenol (Shanghai Sheng Gong bio-engineering corporation, lot number: 020317)；Sodium acetate trihydrate
(one factory of Tianjin chemical reagent, lot number: 020825)；Citric acid (Chengdu Hong He chemical reagent factory, lot number: 020605).
2. experimental method
2.1. preparation of reagents
2.1.1. citric acid preparation method
Citric acid 210.14mg is weighed with electronic balance precision, sets in a 50mL beaker, 20mL is accurately added with pipette
Physiological saline stirs evenly, and filters to get concentration 0.05mol/L, the citric acid solution of pH value 4.5.
2.1.2.STZ preparation method
STZ 41.67mg is weighed with electronic balance precision, is set in a 25mL beaker, 10mL is accurately added with pipette and has matched
Good citric acid solution, stirs evenly, and filters to get concentration 125mg/KgBW.
2.2. rearing conditions
All mouse are raised in IVC barrier system, and 5/box, temperature: 22 ± 3 DEG C, relative humidity: 50%~
80%, illumination: 12h is bright/and 12h is dark (intensity of illumination 150Lux~300Lux), and drinking-water uses sterile water, after all feeds irradiate
It feeds.
2.3. the foundation and administration of animal model of diabetes mellitus type II
3 week old C57BL/6J mouse 45, adaptive feeding is randomly divided into 3 groups by weight after a week, and every group 15, wherein A
Group gives normal diet, and B group, C group give high-sugar-fat-diet, all equal normal waters of mouse.Using docking after three weeks
It is primary that method takes blood to survey the non-fasting blood-glucose of mouse.When seven week old of animal, excipient (0.05mol/L citric acid, pH is injected intraperitoneally in A group
=4.5), every 10g weight injects 0.2mL；B group, C group intraperitoneal injection STZ (125mg/kgBW), every 10g weight inject 0.3mL.
The non-fasting blood sugar of hematometry mouse is taken using docking method after the 4th week respectively after injection of vehicle or STZ.A group continues to give
Normal diet, B group continue to give high-sugar-fat-diet, C group continues to give high-sugar-fat-diet and stomach-filling give embodiment one to
The extract powder 0.8gkg of three gained drugs-1(day for human beings takes 20 times of dosage, middle dosage), one time a day, successive administration 15d.Yu Mo
Fasting 12h after secondary administration measures blood glucose.
2.3. experimental result
2.3.1. animal model of diabetes mellitus type II is established
The results are shown in Table 1 for model foundation.
Table 1 injects mouse blood sugar variation (mmol/L) before and after STZ (125mg/Kg)
Compared with other groups: P < 0.05 *；**P<0.01
From 1 as can be seen that modeling after model group, administration group blood glucose value have extremely significant sex differernce compared with normal group,
And non-fasting blood sugar shows modeling success in 11.0mmol/L or more.
2.3.2. influence of the drug to mouse blood sugar in the present invention
By before measurement modeling, after modeling and after administration mouse blood sugar variation, investigate drug of the present invention to blood glucose
Reduction effect, concrete condition are shown in Table 2.
Influence of 2 Tangping hypoglycemic capsule of table to type II diabetes mouse blood sugar
Compared with normal group: P < 0.01 * P < 0.05, * *；▲ compared with model group: ▲ P < 0.05, ▲ ▲ P < 0.01
From Table 2, it can be seen that blood sugar concentration has extremely significant sex differernce compared with model group after administration, show in the present invention
For treating the composition of diabetes and the drug comprising the composition plays the role of reduces blood glucose, can be used for glycosuria really
The treatment of disease.
Although be described in detail to a specific embodiment of the invention in conjunction with the embodiments, should not be construed as to this
The restriction of the protection scope of patent.In range described by claims, those skilled in the art are without creative work
The various modifications and deformation that can make still belong to the protection scope of this patent.
Claims (9)
1. a kind of for treating the preparation method of the composition of diabetes, which comprises the following steps:
S1: taking the little Hua caulis sinomenii of 5~22 mass parts, and base of leaf separated, and leaf is then cut into the length that width is 0.5~1cm
Stem is ground into the particle that diameter is 2~3mm by item, and extraction 3 times is added water to cook after mixing, and merging filtrate obtains the filter of little Hua caulis sinomenii
Liquid；
S2: the thin slice for taking the balsam pear of 5~33 mass parts, and being cut into a thickness of 0.2~0.5cm adds water to cook extraction 3 times, merges
Filtrate obtains balsam pear filtrate；
S3: merging little Hua caulis sinomenii filtrate and balsam pear filtrate, 60 mesh filter-cloth filterings, and centrifuge separation takes supernatant, straight fire is concentrated into
Relative density be 1.10~1.20 clear cream, be concentrated into 60~70 DEG C of water-baths relative density be 1.30~1.40 it is thick
Cream；
S4: gained thick paste in S3 is uniformly mixed with soluble starch by the mass ratio of 1:2~4, is sieved with 100 mesh sieve, wet process squeezes
Granulation collects the particle between 40~60 meshes, tabletting or loading capsule, obtains drug target.
2. the method according to claim 1, wherein in S1 little Hua caulis sinomenii decoct method particularly includes: first to
The water that 15~20 times of amounts are added in cauline leaf mixture decocts 0.5~1.5h, then 10~15 times of amounts are added in filtering into filter residue
Water decocts 0.5~1.5h, filtering, then the water that 10~15 times are measured is added into filter residue and decocts 0.5~1.5h, and filtering is collected three times
Filtered filtrate obtains little Hua caulis sinomenii filtrate.
3. the method according to claim 1, wherein balsam pear decoction in S2 method particularly includes: first thin to balsam pear
10~15 times of the addition water measured decoct 1.5~3h in piece, filter, and the water decoction 1.5 that then 8~12 times of addition are measured into filter residue~
3h, filtering, then the water that 6~10 times are measured is added into filter residue and decocts 0.5~1h, filtering is collected filtered filtrate three times, is obtained bitter
Melon filtrate.
4. according to the method described in claim 1, it is characterized by: in S3 clear cream relative density be 1.15, the water-bath of clear cream
Thickening temperature is 65 DEG C, and the relative density of thick paste is 1.35.
5. the method according to claim 1, wherein pelletizing in S4 method particularly includes: first thick paste is total with Zhan
The soluble starch of amount 10% is mixed thoroughly, and fine powder is ground into after oven drying, adds remaining soluble starch, and mixing mixes,
It sieves with 100 mesh sieve, wet process squeezes granulation.
6. a kind of for treating the composition of diabetes, which is characterized in that the raw material including following mass parts:
5~22 parts of little Hua caulis sinomenii,
5~33 parts of balsam pear；
The water content of the little Hua caulis sinomenii is 8%~13%, and the water content of the balsam pear is 40%~45%.
7. according to claim 6 for treating the composition of diabetes, which is characterized in that the original including following mass parts
Material:
10 parts of little Hua caulis sinomenii,
15 parts of balsam pear.
8. described in any item for treating the drug of the composition of diabetes comprising claim 6~7.
9. drug according to claim 8, it is characterised in that: the drug is capsule or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910666939.4A CN110215470A (en) | 2019-07-23 | 2019-07-23 | A kind of preparation method of composition and drug and drug for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910666939.4A CN110215470A (en) | 2019-07-23 | 2019-07-23 | A kind of preparation method of composition and drug and drug for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110215470A true CN110215470A (en) | 2019-09-10 |
Family
ID=67813911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910666939.4A Pending CN110215470A (en) | 2019-07-23 | 2019-07-23 | A kind of preparation method of composition and drug and drug for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110215470A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114010668A (en) * | 2021-11-11 | 2022-02-08 | 云南民族大学 | Preparation method of caulis sinomenii extract and application of caulis sinomenii extract in preparation of anti-T2 DM product |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050196474A1 (en) * | 2004-03-03 | 2005-09-08 | Takahiko Anno | Supplement foods and pharmaceuticals |
| CN108272838A (en) * | 2018-03-23 | 2018-07-13 | 三峡大学 | Sabia parviflora Wall.ex Roxb extract and its extracting method and application |
-
2019
- 2019-07-23 CN CN201910666939.4A patent/CN110215470A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050196474A1 (en) * | 2004-03-03 | 2005-09-08 | Takahiko Anno | Supplement foods and pharmaceuticals |
| CN108272838A (en) * | 2018-03-23 | 2018-07-13 | 三峡大学 | Sabia parviflora Wall.ex Roxb extract and its extracting method and application |
Non-Patent Citations (5)
| Title |
|---|
| 张鉴: "《国家非处方药实用手册》", 31 May 2001, 山东科学技术出版社 * |
| 张雪晴: "我国清风藤属药用植物研究概况", 《生物资源》 * |
| 陈艳: "小花清风藤化学成分的研究", 《中草药》 * |
| 雷磊: "糖康胶囊中苦瓜的提取工艺研究", 《时珍国医国药》 * |
| 黄艳: "瑶药毛萼清风藤中总三萜酸的提取工艺优化及含量测定", 《广西科学院学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114010668A (en) * | 2021-11-11 | 2022-02-08 | 云南民族大学 | Preparation method of caulis sinomenii extract and application of caulis sinomenii extract in preparation of anti-T2 DM product |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104107269A (en) | Functional blood sugar-reduction health product and preparation method thereof | |
| CN105055459B (en) | A kind of hypoglycemic composition and purposes | |
| CN110215470A (en) | A kind of preparation method of composition and drug and drug for treating diabetes | |
| CN101028320B (en) | Vegetable medicinal composition with hypoglycemic and hypolipidemic functions and its making method | |
| CN107375430A (en) | A kind of curcumin composition with preventing and treating diabetes and complication | |
| CN1709341A (en) | Medicinal composition for nourishing qi to invigorate spleen, and its preparing method and use | |
| CN101804123B (en) | Plant raw material composition with anti-fatigue effect, preparation method, application and product thereof | |
| CN103599343B (en) | A kind of pharmaceutical composition for the treatment of diabetes and its production and use | |
| CN113663043B (en) | Composition with alpha-glucosidase inhibition effect and preparation method and application thereof | |
| CN107693555A (en) | A kind of medicine and purposes for treating diabetes | |
| CN101491605A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN109260205B (en) | Application of tetrandrine in preparation of medicine for resisting diabetes and hypertension | |
| JP2022511544A (en) | Chinese herbal medicine composition for bowel movement, its preparation method and its use | |
| CN103099865B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN1270737C (en) | Drug for treating gout and method for preparing pill thereof | |
| CN107261079B (en) | Application of longhurendan in preparation of medicine for preventing and/or treating diabetes | |
| CN105455120A (en) | Golden camellia tea assisted blood sugar lowering capsule | |
| CN113648367A (en) | Traditional Chinese medicine micro powder granules for assisting in reducing blood sugar | |
| CN106177416B (en) | A kind of traditional Chinese medicinal composition with effect of reducing blood sugar and preparation method thereof | |
| CN101269123A (en) | Secondary development novel technique for thirst eliminating capsule for lowering blood sugar | |
| CN100484536C (en) | Capsule for treating enteritis and dysentery and its preparing process | |
| CN101491581A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN102366481B (en) | Medicine for treating diabetes and preparation method thereof | |
| CN100353948C (en) | Prescription for treating type 2 diabetes and its preparing method | |
| CN1304018C (en) | Cough-stopping throat-clearing medicament made from chrysanthemum flower |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190910 |
|
| RJ01 | Rejection of invention patent application after publication |